VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Videos  >  

An Analysis of the PANORAMA 1 Trial

Angela Dispenzieri, MD
Published Online:4:13 PM, Fri July 11, 2014
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Clinical Pearls:
  • This was a positive study in terms of progression-free survival. The progression-free survival was about 4 months better in the panobinostat arm.
  • There were significantly more grade 3 toxicities, such as diarrhea, thrombocytopenia and fatigue, in the panobinostat arm.
  • There is no signal in terms of better overall survival.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.